AU 011

Drug Profile

AU 011

Alternative Names: AU-011

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Aura Biosciences; National Cancer Institute (USA)
  • Developer Aura Biosciences
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action Immunostimulants; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Uveal melanoma

Most Recent Events

  • 30 Mar 2017 AU 011 receives Fast Track designation for Uveal melanoma [Intravitreous,Injection] in USA
  • 06 Feb 2017 Phase-I clinical trials in Uveal melanoma (First-line therapy) in USA (Intravitreous) (NCT03052127)
  • 06 Feb 2017 The US FDA approves IND application for AU 011 in Uveal melanoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top